Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: BioCryst Pharmaceuticals, Inc.

Market Cap 2.28B 1.99B 1.85B 1.73B 3.24B 216B 3.26B 21.89B 8.48B 106B 8.58B 8.39B 368B P/E 2026 *
-3.75x
P/E 2027 * 30.9x
Enterprise Value 2.28B 1.99B 1.85B 1.73B 3.24B 216B 3.26B 21.89B 8.48B 106B 8.58B 8.39B 368B EV / Sales 2026 *
3.41x
EV / Sales 2027 * 3.14x
Free-Float
94.36%
Yield 2026 *
-
Yield 2027 * -
12/06 BioCryst Pharmaceuticals' New Clinical Data Demonstrated Reduced Hereditary Angioedema Attacks With Orladeyo Treatment MT
12/06 BioCryst Pharmaceuticals Presents New Clinical Data and Real-World Evidence for HAE Portfolio at the European Academy of Allergy and Clinical Immunology Annual Meeting CI
27/05 BioCryst Pharmaceuticals Presents New HAE Data From ORLADEYO And Navenibart At The European Academy Of Allergy And Clinical Immunology Annual Meeting CI
13/05 BioCryst Pharmaceuticals, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 01:40 PM
07/05 BioCryst Pharmaceuticals, Inc., Q1 2026 Earnings Call, May 06, 2026
07/05 BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
06/05 BioCryst Pharmaceuticals Swings to Q1 Net Loss, Revenue Increases; 2026 Revenue Guidance Reiterated MT
06/05 Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q1 Net Loss $2.98 a Share, vs. FactSet Est of $0.04 EPS MT
06/05 Earnings Flash (BCRX) BioCryst Pharmaceuticals, Inc. Reports Q1 Revenue $156.4M, vs. FactSet Est of $151.1M MT
06/05 BioCryst Pharmaceuticals, Inc. Maintains Earnings Guidance for the Full Year 2026 CI
04/05 BioCryst Pharmaceuticals Enters Licensing Deal for Navenibart With Neopharmed Gentili Affiliate MT
04/05 BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema CI
22/04 Tenax Therapeutics Names Thomas Staab as Chief Financial Officer MT
1 day+0.45%
1 week+3.33%
Current month+0.90%
1 month+2.51%
3 months-8.36%
6 months+21.32%
Current year+15.26%
1 week 8.7
Extreme 8.705
9.54
1 month 8.06
Extreme 8.06
9.54
Current year 6.23
Extreme 6.23
10.32
1 year 6
Extreme 6
10.32
3 years 4.03
Extreme 4.03
11.31
5 years 4.03
Extreme 4.03
19.99
10 years 1.38
Extreme 1.38
19.99
Manager TitleAgeSince
Chief Executive Officer 55 01/01/2026
Director of Finance/CFO 47 07/07/2025
Chief Tech/Sci/R&D Officer - 06/04/2026
Director TitleAgeSince
Director/Board Member 65 01/01/2007
Director/Board Member 65 03/12/2018
Director/Board Member 55 01/01/2026
Date Insider Type Main position Quantity % Market Cap.
11/06Free

Director

48,834 0.0192%
11/06Free

Director

48,834 0.0192%
11/06Free

Director

48,834 0.0192%
Change 5-day change 1-year change 3-year change Capi.($)
+0.45%+3.33%-9.74%+21.32% 2.28B
+1.44%-1.25%+63.52%+114.88% 55.19B
+4.60%+3.02%+58.20%+47.16% 45.75B
-1.44%+0.39%-12.94%-19.24% 22.98B
-2.69%-2.10%-3.68%+379.00% 20.76B
+3.22%-0.84%+27.88%-34.00% 16.26B
+0.58%+1.08%+16.73%-38.06% 15.42B
-1.01%-2.30%+27.42%+171.92% 13.05B
+4.95%+11.70%+123.63%+252.19% 12.45B
+3.07%+0.14%+29.37% - 12.37B
Average +1.32%+2.58%+32.04%+99.46% 21.65B
Weighted average by Cap. +1.62%+1.52%+40.38%+99.03%

Financials

2026 *2027 *
Net sales 671M 585M 542M 507M 951M 63.32B 957M 6.43B 2.49B 31.17B 2.52B 2.46B 108B 727M 634M 587M 550M 1.03B 68.62B 1.04B 6.97B 2.7B 33.78B 2.73B 2.67B 117B
Net income -674M -588M -544M -509M -955M -63.59B -961M -6.46B -2.5B -31.3B -2.53B -2.48B -109B 41.89M 36.53M 33.83M 31.67M 59.39M 3.95B 59.75M 401M 156M 1.95B 157M 154M 6.76B
Net Debt - -
Logo BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of HAE attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX17725, navenibart, Avoralstat, STAR-0310, RAPIACTA (peramivir injection) and PERAMIFLU (peramivir injection). The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Peramivir injection is also approved in Canada (RAPIVAB), Australia (RAPIVAB), Japan (RAPIACTA), Taiwan (RAPIACTA), and Korea (PERAMIFLU). It has also obtained an early-stage program for atopic dermatitis (AD), STAR0310.
Employees
435
Date Price Change Volume
18/06/26 8.990 $ +0.45% 8,882,726
17/06/26 8.950 $ +0.34% 4,450,756
16/06/26 8.920 $ -1.55% 3,575,476
15/06/26 9.060 $ +4.14% 4,153,927
12/06/26 8.700 $ +2.35% 2,394,656
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
8.990USD
Average target price
21.30USD
Spread / Average Target
+136.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BCRX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!